Health Care • Biotechnology: Pharmaceutical Preparations
$2.62 ▲ +0.00
(0.00%)
MKT CAP: $106.1M • VOL: 306.8K
52W L $2 52W H $5
ROARABLE / RQD
D • 46/100
PIOTROSKI
2 / 9
OKUR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$63.0M | -$54.4M | -$36.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$59.5M | -$52.7M | -$35.3M |
| EBITDA (Normalized) | -$62.9M | -$54.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$51.8M | -$51.1M | -$34.5M |
| Capital Expenditures (CapEx) | $46.0K | $52.0K | — |
| Free Cash Flow (FCF) | -$51.9M | -$51.2M | -$34.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $59.0M | $110.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $56.2M | $103.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OKUR.